ADC Therapeutics to Present at J.P. Morgan Healthcare Conference Jan 8

TL;DR

**ADCT presenting at J.P. Morgan conference Jan 8, webcast available.**

AI Summary

ADC Therapeutics SA filed an 8-K on January 4, 2024, to announce that it will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024, at 10:30 AM PST. A live webcast of the presentation will be available on the company's website. This matters to investors because these conferences often reveal new strategic directions, clinical trial updates, or financial outlooks, which can significantly impact the stock price of ADCT.

Why It Matters

Presentations at major healthcare conferences can provide crucial updates on drug development, partnerships, or financial performance, directly influencing investor sentiment and stock valuation.

Risk Assessment

Risk Level: low — This filing is a routine announcement of a conference presentation and does not inherently carry significant risk.

Analyst Insight

A smart investor would mark their calendar for January 8, 2024, to listen to the webcast or review the transcript of ADC Therapeutics SA's presentation for any significant announcements that could affect the stock.

Key Players & Entities

• ADC Therapeutics SA (company) — the registrant filing the 8-K
• J.P. Morgan Healthcare Conference (event) — the conference where ADC Therapeutics will present
• January 4, 2024 (date) — date of the 8-K filing
• January 8, 2024 (date) — date of the presentation
• 10:30 AM PST (time) — scheduled time of the presentation

Forward-Looking Statements

• ADC Therapeutics SA will provide updates on its clinical pipeline or financial outlook during the J.P. Morgan conference presentation. (ADC Therapeutics SA) — medium confidence, target: 2024-01-08

FAQ

Filing Documents

• dp204839_8k-2.htm (8-K) — 24KB
• dp204839_ex9901.htm (EX-99.1) — 36KB
• dp204839_ex9902.htm (EX-99.2) — 47KB
• ex9902_001.jpg (GRAPHIC) — 185KB
• ex9902_002.jpg (GRAPHIC) — 390KB
• ex9902_003.jpg (GRAPHIC) — 218KB
• ex9902_004.jpg (GRAPHIC) — 283KB
• ex9902_005.jpg (GRAPHIC) — 96KB
• ex9902_006.jpg (GRAPHIC) — 261KB
• ex9902_007.jpg (GRAPHIC) — 247KB
• ex9902_008.jpg (GRAPHIC) — 271KB
• ex9902_009.jpg (GRAPHIC) — 223KB
• ex9902_010.jpg (GRAPHIC) — 237KB
• ex9902_011.jpg (GRAPHIC) — 286KB
• ex9902_012.jpg (GRAPHIC) — 184KB
• ex9902_013.jpg (GRAPHIC) — 258KB
• ex9902_014.jpg (GRAPHIC) — 391KB
• ex9902_015.jpg (GRAPHIC) — 221KB
• ex9902_016.jpg (GRAPHIC) — 352KB
• ex9902_017.jpg (GRAPHIC) — 297KB
• ex9902_018.jpg (GRAPHIC) — 286KB
• ex9902_019.jpg (GRAPHIC) — 331KB
• ex9902_020.jpg (GRAPHIC) — 377KB
• ex9902_021.jpg (GRAPHIC) — 333KB
• ex9902_022.jpg (GRAPHIC) — 237KB
• ex9902_023.jpg (GRAPHIC) — 344KB
• ex9902_024.jpg (GRAPHIC) — 238KB
• ex9902_025.jpg (GRAPHIC) — 250KB
• ex9902_026.jpg (GRAPHIC) — 211KB
• image_001.jpg (GRAPHIC) — 4KB
• 0000950103-24-000236.txt ( ) — 9963KB
• adct-20240104.xsd (EX-101.SCH) — 3KB
• adct-20240104_lab.xml (EX-101.LAB) — 33KB
• adct-20240104_pre.xml (EX-101.PRE) — 22KB
• dp204839_8k-2_htm.xml (XML) — 3KB

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition.

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On January 4, 2024, ADC Therapeutics SA (the "Company") issued a press release and made available a corporate presentation that include the preliminary ZYNLONTA net sales for the quarter ended December 31, 2023 and the preliminary cash and cash equivalents as of December 31, 2023. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein. A copy of the corporate presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein. The ZYNLONTA net sales and cash and cash equivalents figures are preliminary and unaudited and reflect the Company's estimated financial results. In preparing this information, management made a number of complex and subjective judgments and estimates about the appropriateness of certain reported amounts and disclosures. The Company's actual financial results for the quarter and year ended December 31, 2023 have not yet been finalized by management or audited or reviewed by the Company's independent auditors. The preliminary financial information is not a comprehensive statement of all financial results for the quarter or year ended December 31, 2023. Subsequent information or events may lead to material differences between the foregoing preliminary financial results and those reported in the Company's subsequent SEC filings. Accordingly, investors should not place undue reliance on these preliminary financial results. The information contained in these Items and Exhibits 99.1 and 99.2 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press release dated January 4, 2024 99.2 Corporate presentation dated January 4, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ADC Therapeutics SA Date: January 4, 2024 By: /s/ Peter J. Graham Name: Peter J. Graham Title: Chief Legal Officer

View Full Filing

View this 8-K filing on SEC EDGAR